Laurens Holmes Jr.
SARS-CoV2 (COVID-19) Pandemic Control and Prevention (eBook, PDF)
An Epidemiological Perspective
47,95 €
47,95 €
inkl. MwSt.
Sofort per Download lieferbar
24 °P sammeln
47,95 €
Als Download kaufen
47,95 €
inkl. MwSt.
Sofort per Download lieferbar
24 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
47,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
24 °P sammeln
Laurens Holmes Jr.
SARS-CoV2 (COVID-19) Pandemic Control and Prevention (eBook, PDF)
An Epidemiological Perspective
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemic to enable better measures for preventions and control.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 2.33MB
This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemic to enable better measures for preventions and control.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 192
- Erscheinungstermin: 29. September 2023
- Englisch
- ISBN-13: 9781000957648
- Artikelnr.: 68794470
- Verlag: Taylor & Francis
- Seitenzahl: 192
- Erscheinungstermin: 29. September 2023
- Englisch
- ISBN-13: 9781000957648
- Artikelnr.: 68794470
Laurens (Larry) Holmes, Jr. is an immunologist and infectious disease specialist, and obtained his doctoral degree in cancer epidemiology and biostatistics from the University of Texas, Health Sciences Center at Houston. He is a Principal Translational Research Scientist, a former Founding Director of the Nemours Paediatric Translational Health Disparities Science research, training and education program, Wilmington, DE (USA), a leading proponent of epigenomic epidemiology in clinical medicine and public health and Affiliate professor of molecular epidemiology and clinical trials at the Biological Sciences Department at the University of Delaware, Newark, DE (USA), Co-founder and Director of Global Health Equity Foundation (GHEF-USA) and Founding Director of Lawhols International Scientific Research Consulting, LIS-RC (USA). Professor Holmes is currently a Director of the Graduate Public Health Program (Epidemiology and Global Health), Public Health & Allied Health Sciences Department, Wesley College-Delaware State University, Dover, DE (USA).
1.Immuno-epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno-epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS-CoV2 (COVID-19): Pandemic and Public Health Emergency Response. 4.SARS-CoV2 Mutation: Immuno-Epidemiologic and Socio-Epidemiologic Response. 5.COVID-19 Pandemic: Epidemic Curve Down-Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS-CoV2 Transmission & COVID-19 Fetal Survivability: Immuno-epidemiologic Perspective. 7.SARS-CoV2 (COVID-19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID-19 Pandemic Global Health Equity Transformation. 9.SARS-CoV2 "Re-emergence" as COVID-19 (2): Translational Public Health and Immuno-epidemiologic Response. 10.SARS-CoV2 (COVID-19) Viral Dynamics Control. 11.Immune System Senescence in SARS-CoV2 Transmission and COVID-19 Clinical Manifestations, Severity and Complications. 12.SARS-CoV2 Exponential Spread and COVID -19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS-CoV2 (COVID-19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS-CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS" and SARS-CoV2 (COVID-19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS-CoV2 (COVID-19) Novel Variants (DELTA), Vaccine Cross-effectiveness and Durability. 17.SARS-CoV2 (COVID-19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities-Blacks/African Americans (AA). 18.SARS-CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case-positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health-related Event in SARS-CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS-CoV2 (COVID-19) Vaccine Effectiveness and Durability in Immunogenic-related Comorbidities (Multiple Myeloma). 21.SARS-CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS-CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS-CoV2 (COVID-19) Morbidity Implication in Chronic Disease (Type II Diabetes -T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS-CoV2 (COVID-19) Pandemic resurgence: Epigenomic Public Health Perspective. 25.SARS-CoV2 (COVID-19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26.Black/African Americans (AA) and Disproportionate Burden of SARS-COV-2 (COVID-19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS-CoV2 and COVID-19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28.Racial/Ethnic and Geo-clustering Differentials in SARS-CoV-2 (COVID-19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
1.Immuno-epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno-epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS-CoV2 (COVID-19): Pandemic and Public Health Emergency Response. 4.SARS-CoV2 Mutation: Immuno-Epidemiologic and Socio-Epidemiologic Response. 5.COVID-19 Pandemic: Epidemic Curve Down-Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS-CoV2 Transmission & COVID-19 Fetal Survivability: Immuno-epidemiologic Perspective. 7.SARS-CoV2 (COVID-19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID-19 Pandemic Global Health Equity Transformation. 9.SARS-CoV2 "Re-emergence" as COVID-19 (2): Translational Public Health and Immuno-epidemiologic Response. 10.SARS-CoV2 (COVID-19) Viral Dynamics Control. 11.Immune System Senescence in SARS-CoV2 Transmission and COVID-19 Clinical Manifestations, Severity and Complications. 12.SARS-CoV2 Exponential Spread and COVID -19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS-CoV2 (COVID-19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS-CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS" and SARS-CoV2 (COVID-19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS-CoV2 (COVID-19) Novel Variants (DELTA), Vaccine Cross-effectiveness and Durability. 17.SARS-CoV2 (COVID-19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities-Blacks/African Americans (AA). 18.SARS-CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case-positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health-related Event in SARS-CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS-CoV2 (COVID-19) Vaccine Effectiveness and Durability in Immunogenic-related Comorbidities (Multiple Myeloma). 21.SARS-CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS-CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS-CoV2 (COVID-19) Morbidity Implication in Chronic Disease (Type II Diabetes -T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS-CoV2 (COVID-19) Pandemic resurgence: Epigenomic Public Health Perspective. 25.SARS-CoV2 (COVID-19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26.Black/African Americans (AA) and Disproportionate Burden of SARS-COV-2 (COVID-19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS-CoV2 and COVID-19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28.Racial/Ethnic and Geo-clustering Differentials in SARS-CoV-2 (COVID-19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA